Compare NTIC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTIC | CRDF |
|---|---|---|
| Founded | 1970 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.9M | 142.1M |
| IPO Year | N/A | N/A |
| Metric | NTIC | CRDF |
|---|---|---|
| Price | $7.46 | $2.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.63 |
| AVG Volume (30 Days) | 41.2K | ★ 892.1K |
| Earning Date | 01-07-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $84,234,474.00 | $501,000.00 |
| Revenue This Year | $7.89 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4,014.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.75 | $1.90 |
| 52 Week High | $14.75 | $5.64 |
| Indicator | NTIC | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 58.01 |
| Support Level | $7.35 | $2.09 |
| Resistance Level | $7.57 | $2.59 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 50.00 | 63.72 |
Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.